7686-29-5

Usage

Appearance

Yellow solid

Solubility

Insoluble in water

Common use

Organic synthesis

Composition

Thiol derivative of nitroaniline

Functional groups

Nitro group and amino group attached to a benzene ring

Application

Building block in the synthesis of pharmaceuticals, dyes, and other organic compounds

Biological activity

Some biological activity and potential medical applications.

Upstream product

• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 
• 2218-96-4 2,4-dinitrothiophenol 
• 15620-71-0 N_.N-Dimethylthiocarbamidsaeure-S-(2.4-dinitrophenylester) 
• 51-28-5 2,4-Dinitrophenol 
• 369-36-8 6-fluoro-3-nitroaniline 
• 10403-47-1 2-bromo 5-nitroaniline 

Downstream Products

• 13599-78-5 5-Nitro-1,2,3-benzothiadiazol 
• 51657-41-1 5,5'-dinitro-2,2'-disulfanediyl-bis-aniline 
• 845658-37-9 2-benzyl-5-nitro-1,3-benzothiazole 
• 945533-85-7 N-(2-(4-chlorophenyl)benzo[d]thiazol-5-yl)isobutyramide 
• 43087-94-1 2-(4-chlorophenyl)benzo[d]thiazol-5-amine 
• 1215113-39-5 2-(4-chlorophenyl)-5-nitrobenzo[d]thiazole 
• 21762-74-3 6-nitro-3,4-dihydro-3-oxo-2H(1,4)benzothiazine 
• 136775-81-0 5-nitro-2-(4-methylphenyl)-benzothiazole 
• 873984-37-3 bis-(2-benzoylamino-4-nitro-phenyl)-disulfide 
• 64448-50-6 5-nitro-2-phenyl-benzothiazole 

Relevant academic research and scientific papers

Selective reduction of nitroaromatic compounds on silver nanoparticles by visible light

For the first time, we report experimentally and theoretically that nitroaromatic compounds, 2,4-dinitrobenzenethiol and 4-chloro-2- nitrobenzenethiol, on silver sols can be selectively reduced to 2-amino-4-nitrobenzenethiol and 2-amino-4-chlorobenzenethiol simply by irradiating with a visible light in ambient conditions, and the selective photoreduction is a very facile process. The results of quantum chemical calculations are in good agreement with our experimental data. Copyright

Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of duchenne muscular dystrophy

Figure Presented. A series of novel 2-arylbenzoxazoles that upregulate the production of utrophin in murine H2K cells, as assessed using a luciferase reporter linked assay, have been identified. This compound class appears to hold considerable promise as a potential treatment for Duchenne muscular dystrophy. Following the delineation of structure-activity relationships in the series, a number of potent upregulators were identified, and preliminary ADME evaluation is described. These studies have resulted in the identification of 1, a compound that has been progressed to clinical trials.

Alpha2C adrenoreceptor agonists

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents - L -R3, in which L is a single bond or a linker group, additionally, R1, R3 - R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A1 - A4 each represent CR1, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR6R7, R6 and R7, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.

Side chain polymers exhibiting nonlinear optical response

This invention provides novel side chain polymers which exhibit nonlinear optical response, and which have utility as a transparent optical component in all-optical and electrooptical light switch and light modulator devices. An invention side chain polymer is illustrated by the following structure: STR1